Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab and Apatinib with chemotherapy in ES-SCLC
NCT04490421Phase 3Unknown
- Sponsor
- 900th Hospital of Joint Logistics Support Force of PLA
- Start
- Aug 2020
- Primary completion
- Aug 2021
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 3, open-label trial of camrelizumab and Rivoceranib in small cell lung cancer (SCLC), sponsored by 900th Hospital of Joint Logistics Support Force of PLA. Status: unknown.
02
Drugs
camrelizumabRivoceranib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT04490421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04490421.